Peter Farkas

Budapest, BU, Hungary

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Two B or not two B; the question of bendamustine dosing in low grade lymphoma.

Two B or not two B; the question of bendamustine dosing in low grade lymphoma.

Journal: Pathology oncology research : POR

Published: June 11, 2025

Changes in the treatment outcomes of light chain amyloidosis - findings of a large center in Budapest

Changes in the treatment outcomes of light chain amyloidosis - findings of a large center in Budapest

Journal: Orvosi hetilap

Published: August 14, 2024

Investigating the effect of immunomagnetic separation on the immunophenotype and viability of plasma cells in plasma cell disorders.

Investigating the effect of immunomagnetic separation on the immunophenotype and viability of plasma cells in plasma cell disorders.

Journal: Pathology oncology research : POR

Published: June 18, 2024

Survival of patients affected with multiple myeloma at the Department of Internal Medicine and Haematology of Semmelweis University

Survival of patients affected with multiple myeloma at the Department of Internal Medicine and Haematology of Semmelweis University

Journal: Orvosi hetilap

Published: June 15, 2024

How did the survival of acute myeloid leukemia change over the last ten years in our unit?

How did the survival of acute myeloid leukemia change over the last ten years in our unit?

Journal: Orvosi hetilap

Published: July 27, 2023

Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation.

Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation.

Journal: The journal of pathology. Clinical research

Published: July 26, 2023

Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax.

Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax.

Journal: International journal of molecular sciences

Published: February 02, 2023

Cardiac Amyloidosis with Normal Wall Thickness: Prevalence, Clinical Characteristics and Outcome in a Retrospective Analysis.

Cardiac Amyloidosis with Normal Wall Thickness: Prevalence, Clinical Characteristics and Outcome in a Retrospective Analysis.

Journal: Biomedicines

Published: July 05, 2022

Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry.

Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry.

Journal: Pathology oncology research : POR

Published: June 17, 2022

Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen.

Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen.

Journal: Blood

Published: May 04, 2022

Screening and monitoring of the BTKC481S mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy.

Screening and monitoring of the BTKC481S mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy.

Journal: British journal of haematology

Published: January 25, 2021

Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.

Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.

Journal: Pathology

Published: December 04, 2020

Showing 1-12 of 32

Last Updated: 09/26/2026